When is it safe to discontinue TKI therapy in people with chronic myeloid leukemia?
Some patients reach a point where ongoing TKI therapy can cause more harm than good. New data can simplify the decision to discontinue treatment.
Dr. Ehab Atallah
Ehab Atallah, MD, is a Professor of Medicine and Section Head of hematological malignancies in the Medical College of Wisconsin Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital. He graduated from Cairo University School of Medicine in 1994, then completed an internal medicine residency in the Cleveland Clinic Health System and a fellowship in hematology/oncology at the Karmanos Cancer Center in Detroit, Michigan, where he served as Chief Fellow. Subsequently he completed a leukemia fellowship at M.D. Anderson Cancer Center in Houston, Texas. Dr. Atallah is board certified in Internal Medicine and Hematology. In 2007, he received the American Society of Clinical Oncology Foundation Merit Award. Ehab is currently the administrative director of the H Jean Khoury Cure CML consortium. He is working with CML experts across the nation to improve the outcome of patients with CML, and he has authored numerous publications.